我国和WHO基本药物目录中治疗2型糖尿病药物比较分析  

Comparative Analysis of the Medicines for the Treatment of Type 2 Diabetes between the National Essential Medicines List and the WHO Model List of Essential Medicines

作　　者：唐筱婉 唐彦 左玮 孙雯娟 张波[1] Tang Xiaowan;Tang Yan;Zuo Wei;Sun Wenjuan;Zhang Bo(Department of Pharmacy,Pecking Union Medical College Hospital Affiliatedto the Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院药剂科

出　　处：《中国药师》2019年第6期1099-1102,共4页China Pharmacist

基　　金：国家自然科学基金项目(编号:81601033);北京市自然科学基金项目(编号:7174342);中国医学科学院医学与健康科技创新工程项目(编号:2017-I2M1-011)

摘　　要：目的:比较2012年版、2018年版《国家基本药物目录》与2017年版世界卫生组织(WHO)《基本药物标准清单》中治疗2型糖尿病药物的异同,为进一步完善我国基本药物目录提供参考。方法:采用描述性分析的方法比较目录中治疗2型糖尿病药物的品种、数量、剂型、规格的差异,对此类药物的目录特点、优劣及存在的问题进行分析。结果:与WHO《基本药物标准清单》相比,《国家基本药物目录》收录的治疗2型糖尿病药物品种更多,与我国疾病负担基本相符,2018年版《国家基本药物目录》调整后不同作用机制的降糖药物均有覆盖;但同类药物的遴选与调入调出尚存在不合理之处。结论:2018年版《国家基本药物目录》治疗2型糖尿病药物目录的合理性有所提高,但与WHO《基本药物标准清单》相比,同类药物的遴选、调入和调出标准以及循证医学证据的引入还有待进一步提高。WHO《基本药物标准清单》对我国持续修订和完善国家基本药物目录具备借鉴作用和指导价值。Objective:To understand the difference in the medicines for the treatment of type 2 diabetes between the National Essential Medicines List(2012 C-EML),(2018 C-EML)and the WHO Essential Medicines Model List(2017 WHO-EML)in order to provide reference for the revision of C-EML in the future.Methods:The differences in the variety,number,dosage forms and specifications were compared by descriptive analysis,and the characteristics,pros and cons and problems were also analyzed.Results:Compared with the WHO-EML,C-EML contains more medicines for the treatment of type 2 diabetes,which is basically consistent with the disease burden of China.After the adjustment of C-EML in 2018,hypoglycemic drugs with different action mechanisms are all covered.However,there are still some unreasonable problems in the selection and transfer of similar medicines.Conclusion:The rationality of 2018 C-EML was improved,while the selection and transfer of similar medicines and the introduction of evidence-based medical evidence needs should be further improved when compared to those in the WHO-EML.The study provides reference and guidance to the revision and improvement of C-EML.

关 键 词：基本药物 基本药物目录 世界卫生组织 治疗2型糖尿病药物 

分 类 号：R924[医药卫生—药学]